Sentences with phrase «preclinical trial with»

Three years after publishing a groundbreaking paper in which she isolated adult retinal pigment epithelial stem cells, Temple is in preclinical trials with rats.

Not exact matches

Preclinical trials indicate potential for noscapine as a cancer drug with less toxicity to healthy cells than currently available chemotherapies.

If the prevention trials fail, it will be up to academics to persuade companies back to the table with solid preclinical and early clinical data, says Mucke.

It's a kind of checklist of the testing conditions and experiments necessary to proceed with preclinical and human trials.

Independent of these preclinical studies, Clementia Pharmaceuticals is currently conducting phase 2 clinical trials in individuals with FOP, based on the 2011 preclinical results published by Pacifici and Iwamoto.

Flake's team has patented the device and is in consultation with the Food and Drug Administration to plan a preclinical trial in animals as a prelude to doing a trial in humans.

Both have shown preclinical promise, and the lipid nanoparticle approach was used with patisiran to great effect in Alnylam's positive trial.

Researchers suggested that other classes of inhibitors be tested in combination with ERK5 inhibitors in human colorectal cancer cells in preclinical mouse models before any patient trial can begin.

In a small preclinical trial, 10 healthy volunteers drank or swished fruit juice mixed with broccoli sprout extract for several days.

UNITY has completed a rigorous screening and preclinical testing process of candidate drugs, discovered in this study, and is launching a new clinical trial to assess its first drug, for patients with osteoarthritis of the knee this year.

Based on these preclinical findings, CRI provides a seed grant for a phase I clinical trial to test the strategy in patients with metastatic renal cell carcinoma.

PsychoGenics has pioneered the translation of rodent behavioral responses into robust, high throughput, high content phenotyping and its drug discovery platforms, SmartCube ®, NeuroCube ®, and PhenoCube ® have led to shared risk partnerships with major pharma companies such as Sunovion and Roche and resulted in the discovery of several novel compounds now in clinical trials or advanced preclinical development.

These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, uncertainty regarding potential future deterioration in the market for auction rate securities which could result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

The $ 1 million grant will be used for preclinical trial work with the goal of submitting an Investigational New Drug application to the FDA to begin clinical trials.

«Lithium, long used in mental health as a highly effective mood stabiliser, has been on the radar as a potential disease modifying treatment for Alzheimer's disease with positive evidence from preclinical studies and a number of small clinical trials.

Preclinical studies suggested poor bioavailability with a consequent in vivo ineffectiveness for compound 182a [2, 97], while compound 182b entered clinical trials, unfortunately its development was soon suspended [98, 99].

It is currently being evaluated for safety and efficacy in preclinical models with a Phase I trial expected to begin in 2019.

Another mouse preclinical screening trial targeted the symptomatic stage (between 9 and 11 months)[44] and a study with a plant extract [99] used 23 - to 24 - month - old mice, but to our knowledge no chemically defined AD drug candidate has been tried at the more pathologically advanced stage used in this study.

In an effort to further exploit the potential of Pexa - Vec to activate the immune system to fight cancer, as seen in McDonald's preclinical data, SillaJen recently announced a new clinical trial in collaboration with New York - based Regeneron Inc. to test Pexa - Vec and REGN2810, a PD - 1 checkpoint inhibitor, in combination against renal cell carcinoma, and recently signed a sponsored research agreement with UCSF to enable joint support of parallel preclinical experiments by McDonald's team.

Our researcher received a proof - of - concept grant from the Washington Life Sciences Discovery Fund, and worked with Washington State University and Malignext to conduct preclinical trials that produced results that will be helpful in future preclinical and clinical trials.

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Prothena Corporation plc (NASDAQ: PRTA), announced today that they have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha - synuclein, including PRX002... which is currently in preclinical development and is expected to enter Phase 1 clinical trials in patients with Parkinson's disease in 2014.

Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

«It will obviously be critical to check that there are few and hopefully no problems with the new methods, but as far as I know, the preclinical trials look very promising.»

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the outcome of the review of the continued listing of our common stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

Our preclinical data on DG041 were very encouraging and we look forward to sharing with you the results of this trial in a few months time,» said Kari Stefansson, CEO of deCODE.

The Delaney Collaboratory to Cure HIV - 1 Infection by Combination Immunotherapy (BEAT - HIV Collaboratory) is a consortium of more than 30 top HIV researchers from leading academic research institutions working with government, nonprofit organizations, and industry partners to test combinations of several novel immunotherapies under new preclinical research and clinical trials.

However, ADCs that use derivatives of calicheamicin, which promotes double - stranded DNA breaks, such as GO and inotuzumab ozogamicin, 40,41 have limited activity in cells with high multidrug resistance protein activity, a phenotype found in a significant fraction of AML patients.42 Another ADC, SGN - CD123A, comprising an engineered form of the CD123 - targeting 7G3 antibody conjugated to a synthetic pyrrolobenzodiazepine dimer, which acts via DNA crosslinking, has entered clinical trials after showing robust activity in preclinical models of AML, including those with multidrug resistance.33

These preclinical studies have led to a clinical trial for patients with glioblastoma multiforme (www.clinicaltrials.gov NCT02046187).

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study — A Randomized Clinical Trial.

Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC Study - a randomized clinical trial.

The trial, titled «Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease (MMVD) and Cardiomegaly» (EPIC), is the largest clinical study ever to be conducted in veterinary cardiology.